Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical trial databases

This article was originally published in The Gray Sheet

Executive Summary

FDA Center for Drug Evaluation and Research issues March 29 guidance for establishing a databank for drug clinical trials as mandated by the FDA Modernization Act. The guidance recommends that trial sponsors submit data in four areas: descriptive information (title, protocol summary, study design/phase/type, condition or disease, intervention); recruitment information (study status, eligibility criteria/gender/age); location and contact information; and administrative data. A Health and Human Services report to Congress last November recommended postponement of such a database for device trials until 2001 so as to accumulate experience with the drug database first (1"The Gray Sheet" Dec. 6, p. 6)

You may also be interested in...



HHS Suggests Congress Delay Device Trials Registry Decision Until 2001

Congress should delay action on creating a device trials registry until the year 2001, "after there is one year of experience with data from privately funded trials in the drug trials registry," Secretary of Health and Human Services Donna Shalala concludes in a report on the need for and impact of a device clinical trials databank.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

UsernamePublicRestriction

Register

MT013180

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel